safety 1
tolerability 1
eltrombopag 1
versus 1
placebo 1
treatment 1
thrombocytopenia 1
patients 1
advanced 1
myelodysplastic 1
syndromes 1
acute 1
myeloid 1
leukaemia 1
multicentre 1
randomised 1
placebocontrolled 1
doubleblind 1
phase 2
trial 1
study 1
cladribine 1
cytarabine 1
arac 1
granulocyte 1
colony 1
stimulating 1
factor 1
gcsf 1
clag 1
regimen 1
simultaneous 1
escalating 1
doses 1
imatinib 1
mesylate 1
gleevec 1
relapsedrefractory 1
aml 1
